keyword
MENU ▼
Read by QxMD icon Read
search

lifitegrast

keyword
https://www.readbyqxmd.com/read/27906544/lfa-1-icam-1-interaction-as-a-therapeutic-target-in-dry-eye-disease
#1
Stephen C Pflugfelder, Michael Stern, Steven Zhang, Amir Shojaei
Dry eye disease (DED) is a common ocular disorder associated with inflammation of the lacrimal gland and ocular surface. The interaction of the integrin lymphocyte function-associated antigen-1 (LFA-1) with its cognate ligand intercellular adhesion molecule-1 (ICAM-1) is known to have important roles in the interaction of a variety of cells involved in immune responses and inflammation, including those prominent in ocular surface inflammation. Lifitegrast, an LFA-1 antagonist that blocks binding of ICAM-1 to LFA-1, has recently been approved in the United States for the treatment of signs and symptoms of DED...
December 1, 2016: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27883115/lifitegrast-first-lfa-1-icam-1-antagonist-for-treatment-of-dry-eye-disease
#2
D M Paton
Dry eye disease is an extremely common condition affecting millions worldwide. The underlying pathophysiological mechanism is thought to be localized inflammation of the ocular surface resulting in the localization of T cells at this surface followed by their activation and subsequent liberation of cytokines. This effect on T cells results from the binding of lymphocyte function-associated antigen-1 (LFA-1) located on T cells to intercellular adhesion molecule 1 (ICAM-1) expressed on inflamed epithelium and endothelium, and on T cells...
September 2016: Drugs of Today
https://www.readbyqxmd.com/read/27559192/sugammadex
#3
Dennis J Cada, Terri L Levien, Danial E Baker
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers...
July 2016: Hospital Pharmacy
https://www.readbyqxmd.com/read/27552207/lifitegrast-xiidra-for-dry-eye-disease
#4
(no author information available yet)
No abstract text is available yet for this article.
August 29, 2016: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/27388660/lifitegrast-clinical-efficacy-for-treatment-of-signs-and-symptoms-of-dry-eye-disease-across-three-randomized-controlled-trials
#5
Edward J Holland, Walter O Whitley, Kenneth Sall, Stephen S Lane, Aparna Raychaudhuri, Steven Y Zhang, Amir Shojaei
OBJECTIVE: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED). RESEARCH DESIGN AND METHODS: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed. MAIN OUTCOME MEASURES: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0-4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0-4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0-100)...
July 22, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27354762/development-of-lifitegrast-a-novel-t-cell-inhibitor-for-the-treatment-of-dry-eye-disease
#6
REVIEW
Charles P Semba, Thomas R Gadek
Dry eye disease (DED) is a multifactorial disorder of the ocular surface characterized by symptoms of discomfort, decreased tear quality, and chronic inflammation that affects an estimated 20 million patients in the US alone. DED is associated with localized inflammation of the ocular surface and periocular tissues leading to homing and activation of T cells, cytokine release, and development of hyperosmolar tears. This inflammatory milieu results in symptoms of eye dryness and discomfort. Homing of T cells to the ocular surface is influenced by the binding of lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2), a cell surface adhesion protein, to its cognate ligand, intercellular adhesion molecule-1 (ICAM-1; CD54), which is expressed on inflamed ocular/periocular epithelium and vascular endothelium...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27055211/safety-of-lifitegrast-ophthalmic-solution-5-0-in-patients-with-dry-eye-disease-a-1-year-multicenter-randomized-placebo-controlled-study
#7
Eric D Donnenfeld, Paul M Karpecki, Parag A Majmudar, Kelly K Nichols, Aparna Raychaudhuri, Monica Roy, Charles P Semba
PURPOSE: To evaluate the 1-year safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease compared with placebo. METHODS: SONATA (Safety Of a 5.0% coNcentrATion of lifitegrAst ophthalmic solution) was a multicenter, randomized, prospective, double-masked, placebo-controlled phase 3 study (NCT01636206). Adults (≥18 years) with dry eye disease (Schirmer test score ≥1 and ≤10 mm; corneal staining score ≥2.0) were randomized 2:1 to lifitegrast ophthalmic solution 5...
June 2016: Cornea
https://www.readbyqxmd.com/read/26807723/lifitegrast-a-novel-integrin-antagonist-for-treatment-of-dry-eye-disease
#8
REVIEW
Victor L Perez, Stephen C Pflugfelder, Steven Zhang, Amir Shojaei, Reza Haque
The etiology of dry eye disease (DED) is complex and not yet fully understood, but the disease is now recognized as being associated with ocular surface inflammation. The latest advances in the understanding of the pathophysiology of DED have directed the focus of recent drug development to target the inflammatory pathways involved in the disease. Lifitegrast is a novel small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus lessening overall inflammatory responses...
April 2016: Ocular Surface
https://www.readbyqxmd.com/read/26365210/lifitegrast-ophthalmic-solution-5-0-versus-placebo-for-treatment-of-dry-eye-disease-results-of-the-randomized-phase-iii-opus-2-study
#9
RANDOMIZED CONTROLLED TRIAL
Joseph Tauber, Paul Karpecki, Robert Latkany, Jodi Luchs, Joseph Martel, Kenneth Sall, Aparna Raychaudhuri, Valerie Smith, Charles P Semba
PURPOSE: Lifitegrast is an integrin antagonist that decreases T-cell-mediated inflammation associated with dry eye disease (DED). We report the results of OPUS-2, a phase III study evaluating the efficacy and safety of lifitegrast compared with placebo for the treatment of DED. DESIGN: A 12-week, multicenter, randomized, prospective, double-masked, placebo-controlled clinical trial. PARTICIPANTS: Adults aged ≥18 years with use of artificial tears within 30 days, inferior corneal staining score ≥0...
December 2015: Ophthalmology
https://www.readbyqxmd.com/read/24289915/lifitegrast-ophthalmic-solution-5-0-for-treatment-of-dry-eye-disease-results-of-the-opus-1-phase-3-study
#10
RANDOMIZED CONTROLLED TRIAL
John D Sheppard, Gail L Torkildsen, John D Lonsdale, Francis A D'Ambrosio, Eugene B McLaurin, Richard A Eiferman, Kathryn S Kennedy, Charles P Semba
PURPOSE: To assess the efficacy and safety of lifitegrast ophthalmic solution 5.0% compared with placebo in subjects with dry eye disease. DESIGN: Prospective, randomized, double-masked, placebo-controlled, parallel arm, multicenter clinical trial. PARTICIPANTS: A total of 588 adult subjects with dry eye disease. METHODS: Eligible subjects were randomized 1:1 to receive topically administered lifitegrast (5.0%) or placebo (vehicle) twice daily for 84 days after a 14-day open-label placebo run-in period...
February 2014: Ophthalmology
https://www.readbyqxmd.com/read/23215542/corneal-inflammation-is-inhibited-by-the-lfa-1-antagonist-lifitegrast-sar-1118
#11
Yan Sun, Rui Zhang, Thomas R Gadek, Charles A O'Neill, Eric Pearlman
PURPOSE: Sterile corneal infiltrates can cause pain, blurred vision, and ocular discomfort in silicone hydrogel contact-lens users. The current study investigates the potential for the synthetic lymphocyte functional antigen-1 (LFA-1) antagonist lifitegrast (SAR 1118) to block corneal inflammation using a murine model. METHODS: The role of LFA-1 (CD11a/CD18) was examined either in CD18(-/-) mice, by intraperitoneal injection of anti-CD11a, or by topical application of lifitegrast...
May 2013: Journal of Ocular Pharmacology and Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"